Frontiers in diabetic nephropathy: Can we predict who will get sick?

Journal of the American Society of Nephrology

Volumn 17, Issue 2, 2006, Pages 336-338

  Sedor, John R ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; GLUCOSE;

CHRONIC DISEASE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; EDITORIAL; GENE INTERACTION; GENOTYPE PHENOTYPE CORRELATION; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HIGH RISK POPULATION; HUMAN; KIDNEY FAILURE; PATIENT EDUCATION; PRIORITY JOURNAL;

EID: 33645453729     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005121245     Document Type: Editorial

References (34)

1. US Renal Data System: USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. US Renal Data System, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2005
2. Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA: Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J (Clin Res Ed.) 294: 1443-1447, 1987
3. UKPDS Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 317: 703713, 1998
4. UKPDS Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352: 837-853, 1998
5. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329: 977-986, 1993
6. Diabetes Control and Complications Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342: 381-389, 2000
7. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; for the Collaborative Study Group: The effect of angiotensin-converting enzyme therapy on diabetic nephropathy. N Engl J Med 329: 1456-1462, 1993
8. Hostetter TH: Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 345: 910-912, 2001
9. Hicks LS, Fairchild DG, Horng MS, Orav EJ, Bates DW, Ayanian JZ: Determinants of JNC VI guideline adherence, intensity of drug therapy, and blood pressure control by race and ethnicity. Hypertension 44: 429-434, 2004
10. Satterfield DW, Volansky M, Caspersen CJ, Engelgau MM, Bowman BA, Gregg EW, Geiss LS, Hosey GM, May J, Vinicor F: Community-based lifestyle interventions to prevent type 2 diabetes. Diabetes Care 26: 2643-2652, 2003
11. Bowman BA, Gregg EW, Williams DE, Engelgau MM, Jack L Jr: Translating the science of primary, secondary, and tertiary prevention to inform the public health response to diabetes. J Public Health Manag Pract 9: S8-S14, 2003
12. Neumann PJ, Rosen AB, Weinstein MC: Medicare and cost-effectiveness analysis. N Engl J Med 353: 1516-1522, 2005
13. Rowland D: Medicaid-Implications for the health safety net. N Engl J Med 353: 1439-1441, 2005
14. Mogensen CE, Christensen CK: Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 311: 89-93, 1984
15. Caramori ML, Fioretto P, Mauer M: Augmenting the predictive value of urinary albumin for diabetic nephropathy. J Am Soc Nephrol 17: 339-352, 2006
16. Rich S: Genetics of diabetes and its complications. J Am Soc Neph 17: 353-360, 2006
17. Quinn M, Angelico MC, Warram JH, Krolewski AS: Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 39: 940-945, 1996
18. Seaquist ER, Goetz FC, Rich S, Barbosa J: Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 320: 1161-1165, 1989
19. Fogarty DG, Rich SS, Hanna L, Warram JH, Krolewski AS: Urinary albumin excretion in families with type 2 diabetes is heritable and genetically correlated to blood pressure. Kidney Int 57: 250-257, 2000
20. Fogarty DG, Hanna LS, Wantman M, Warram JH, Krolewski AS, Rich SS: Segregation analysis of urinary albumin excretion in families with type 2 diabetes. Diabetes 49: 1057-1063, 2000
21. Imperatore G, Knowler WC, Pettitt DJ, Kobes S, Bennett PH, Hanson RL: Segregation analysis of diabetic nephropathy in Pima Indians. Diabetes 49: 1049-1056, 2000
22. Susztak K, Bottinger EP: Diabetic nephropathy: A frontier for personalized medicine. J Am Soc Neph 17: 361-367, 2006
23. Susztak K, Bottinger E, Novetsky A, Liang D, Zhu Y, Ciccone E, Wu D, Dunn S, McCue P, Sharma K: Molecular profiling of diabetic mouse kidney reveals novel genes linked to glomerular disease. Diabetes 53: 784-794, 2004
24. Susztak K, Ciccone E, McCue P, Sharma K, Bottinger EP: Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLoS Med 2: 152-161, 2005
25. Galkina E, Ley K: Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Neph 17: 368-377, 2006
26. Nadeau JH: Listening to genetic background noise. N Engl J Med 352: 1598-1599, 2005
27. Hubner N, Wallace CA, Zimdahl H, Petretto E, Schulz H, Maciver F, Mueller M, Hummel O, Monti J, Zidek V, Musilova A, Kren V, Causton H, Game L, Born G, Schmidt S, Muller A, Cook SA, Kurtz TW, Whittaker J, Pravenec M, Aitman TJ: Integrated transcriptional profiling and linkage analysis for identification of genes underlying disease. Nat Genet 37: 243-253, 2005
28. Schadt EE, Lamb J, Yang X, Zhu J, Edwards S, Guhathakurta D, Sieberts SK, Monks S, Reitman M, Zhang C, Lum PY, Leonardson A, Thieringer R, Metzger JM, Yang L, Castle J, Zhu H, Kash SF, Drake TA, Sachs A, Lusis AJ: An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet 37: 710-717, 2005
29. Bystrykh L, Weersing E, Dontje B, Sutton S, Pletcher MT, Wiltshire T, Su AI, Vellenga E, Wang J, Manly KF, Lu L, Chesler EJ, Alberts R, Jansen RC, Williams RW, Cooke MP, de Haan G: Uncovering regulatory pathways that affect hematopoietic stem cell function using 'genetical genomics'. Nat Genet 37: 225-232, 2005
30. Schadt EE, Monks SA, Friend SH: A new paradigm for drug discovery: Integrating clinical, genetic, genomic and molecular phenotype data to identify drug targets. Biochem Soc Trans 31: 437-443, 2003
31. Knowler WC, Coresh J, Elston RC, Freedman BI, Iyengar SK, Kimmel PL, Olson JM, Plaetke R, Sedor JR, Seldin MF; Family Investigation of Nephropathy and Diabetes Research Group: The Family Investigation of Nephropathy and Diabetes (FIND): Design and methods. J Diabetes Complications 19: 1-9, 2005
32. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 22: 99-111, 1999
33. Breyer MD, Bottinger E, Brosius FC 3rd, Coffman TM, Harris RC, Heilig CW, Sharma K; for the AMDCC: Mouse models of diabetic nephropathy. J Am Soc Nephrol 16: 27-45, 2005
34. Qi Z, Fujita H, Jin J, Davis LS, Wang Y, Fogo AB, Breyer MD: Characterization of susceptibility of inbred mouse strains to diabetic nephropathy. Diabetes 54: 2628-2637, 2005